Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals

Clinical Pharmacokinetics

Volumn 44, Issue 1, 2005, Pages 99-109

  Smith, Patrick F ^a,b   DiCenzo, Robert ^a   Forrest, Alan ^a   Shelton, Mark ^a   Friedland, Gerald ^b   Para, Michael ^b   Pollard, Richard ^b   Fischl, Margaret ^b,c   DiFrancesco, Robin ^a,b   Morse, Gene D ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DISPOSITION; DRUG DISTRIBUTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BODY WEIGHT; CARBAMAZEPINE; CONTINENTAL POPULATION GROUPS; DELAVIRDINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; SEX FACTORS;

EID: 19944426706     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200544010-00004     Document Type: Article

References (18)

1. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283 (3): 381-90
2. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001; 40 (12): 893-905
3. Ferry JJ, Herman BD, Carel BJ, et al. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (3): 252-9
4. van Heeswijk RP, Veldkamp AI, Hoetelmans RM, et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999; 13 (14): F95-9
5. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both, in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis 2000; 182 (5): 1375-84
6. Morse G, Para M, Fischl M, et al. Concentration-targeted delavirdine therapy in 82 patients in ACTG 260. 3rd Conference on Retroviruses and Opportunistic Infection; 1996 Jan 28-Feb 1; Washington, DC, 118
7. Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 2002; 18 (12): 825-34
8. Friedland GH, Pollard R, Griffith B, et al. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. J Acquir Immune Defic Syndr 1999; 21 (4): 281-92
9. Para MF, Meehan P, Holden-Wiltse J, et al. ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. Antimicrob Agents Chemother 1999; 43 (6): 1373-8
10. Magee M, Forrest A, Shelton M, et al. A novel pharmacokinetic/ pharmacodynamic model for delavirdine monotherapy [abstract]. 101st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2000 Mar 15-17; Los Angeles
11. Akaike H. A Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 1979; 66: 237-42
12. Jusko WJ. Guidelines for collection and analysis of pharmacokinetic data. In: Evans WJJ, Schentag JJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vol. 2. Vancouver (WA): Applied Therapeutics Inc., 1992: 1-43
13. Collins D, Forrest A. IT2S user's guide. Buffalo (NY): State University of New York at Buffalo, 1995
14. Steimer JL, Mallet A, Golmard JL, et al. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev 1984; 15 (1-2): 265-92
15. Product information: Rescriptor(R), delavirdine. Kalamazoo (MI): Pharmacia & Upjohn Company, 1999
16. Akbar B, Shelton MJ, Adams JM, et al. Effects of Helicobacter pylori treatment on gastric pH and delavirdine mesylate pharmacokinetics in HIV+ patients with gastric hypoacidity [abstract A56]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sep 15-18 1996; New Orleans
17. Shelton MJ, Adams JM, Hewitt RG, et al. Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. Clin Infect Dis 1998; 27 (4): 739-45
18. Morse GD, Fischl MA, Shelton MJ, et al. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997; 41 (1): 169-74